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Suzanne A. Sprunger & Gianna Julian-Arnold*
Introduction
What is the appropriate balance between encouraging
biotechnological innovation while protecting the public from risks that
accompany any new technology? A conference was convened 1 to
address a concern that, as biotechnology develops at breakneck speed,
even rapidly adapting legal systems2 neither promote genome-related
innovation effectively, nor adequately address public worries about
product safety and control of genetic information. The conference was
a sequel to an earlier one that focused on intellectual property and
technology transfer.
3
Presentation topics included societal issues raised by genomic
innovation, the role of intellectual property in promoting research and
development, and the effects of legal regulation of pre- and postmarket
testing - as well as case studies of vaccine development, bioremed-
iation and genome sequence database creation.
Elaine Draper made the first formal presentation, pointing out that
not all innovation is necessarily good. She identified possible
employment discrimination and social stratification as undesirable
0 Dr. Sprunger received her B.S. (Biology) from Cornell University, Ph.D.
(Genetics) from the University of Wisconsin-Madison and J.D. from Franklin Pierce
Law Center (FPLC).
Ms. Julian-Arnold is an Associate with Roberts & Brownell, Tysons Corner, VA.
She received her B.S. (Chemistry) from Northern Arizona University and her J.D. and
M.I.P. from FPLC.
I October 1995. Organized by Professor Thomas G. Field, Jr. and Gianna Julian-
Arnold, the conference was funded in part by the Ethical, Legal and Social Issues
component of the D.O.E. Human Genome Program; Nixon, Hargrave, Devans &
Doyle L.L.P., Rochester, N.Y.; and Human Genome Sciences. We are grateful for
that support.
2 Recent changes include, e.g., an amendment to 35 U.S.C. § 103 & 282, PL
104-41 § 1111, Nov. 1, 1995, (facilitating the patenting and protection of biotech
processes) and amendments to FDA regulations to eriminate some hurdles for
approval of biotechnology products. With regard to the latter, see Lauran Neergaard,
FDA Eases Rules for Biotech Drugs, AP, Nov. 9, 1995, 1995 WL 4413545.
3 July 1993. Human Genome Symposium, 5(2) Risk (1994) (at 95-188).
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consequences of genome research. Among other things, Dr. Draper
suggested that statutes designed to protect employees from
discrimination be extended to cover those with genetic predispositions
for disease.4
Kate Murashige followed, acknowledging that some technologies
present problems, as patents themselves sometimes do. She nevertheless
stressed the importance of private risk capital in supporting research and
development and patents in attracting it. She also discussed several
ways the patent system fails to provide adequate incentives for certain
types of inventions.5
Phillip Russell focused on a technology with little if any downside.
He discussed how biotechnology can meet a global need for more
effective vaccines. He also addressed several compelling obstacles,
including various kinds of bureaucratic and logistical problems. In
passing, he noted that while patent protection provides an investment
incentive, it may interfere with commercial availability of logistically
optimal combinations of proprietary vaccines. 6
Brian Cunningham illustrated how policies for regulating the use of
biotechnology develop in practice. From his experience, he endorsed a
suggestion for a federal bioethical commission. He found such an
institution to be potentially helpful in reassuring the public and
shrinking the gap between the rapid development of biotechnology and
the slow develoment of guidelines for its use. 7
Karin Gregory8 discussed Institutional Review Boards (IRBs) as a
means for protecting clinical subjects in premarket testing of new
medical products, however derived. She suggested that one reason IRBs
are needed is because investigators can have several roles: scientist, agent
4 Elaine Alma Draper, Social Issues of Genome Innovation and Intellectual
Property, 7 Risk 201 (1996) (includes brief biographical information).
5 Kate H. Murashige, Genome Research and Traditional Intellectual Property
Protection - A Bad Fit? 7 Risk 231 (1996) (includes brief biographical information).
6 Phillip K. Russell, Development of Vaccines to Meet Public Health Needs:
Incentives and Obstacles, 7 Risk (1996) 239 (includes brief biographical information).
7 Brian C. Cunningham, Impact of the Human Genome Project at the Interface
between Patent and FDA Laws, 7 Risk 253 (1996) (includes brief biographical
information).
8 Ms. Gregory, a lawyer vho also holds an M.P.H. practices in Boston.
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of the drug sponsor and treating physician. She explained how IRBs,
made up of both health-care professionals and lay citizens, must ensure,
for example, that patients are advised of significant side effects in
informed consent forms that can be understood. She also noted that
IRBs may even play a role in designing or redesigning clinical studies.
Jeffrey Gibbs discussed the role of the Food and Drug
Administration (FDA) in premarket testing and sanctions that it can
bring to bear on those who fail to conform to legal requirements. He
also discussed how action by the FDA, both before and after
marketing, can have a major effect on manufacturers' potential civil
liability to those who suffer adverse consequences. 9
Michael Connolly10 presented a paper recounting how hazardous
waste regulation both encourages and discourages biotechnological
development. As he explained, despite the very large apparent promise
of bioremediation, 11 it is projected to represent only about 3% of the
$1.7 trillion market in technologies used to clean up hazardous sites
over the next twenty years. He also suggested ways bioremediation
might be more fully exploited to improve the environment.
Finally, Robert Benson 12 related the experience of Human
Genome Sciences (HGS) in attempting to recoup the costs of data
generated by its affiliate, The Institute for Genetic Research (TIGR).
TIGR currently concentrates on cDNA sequences that represent
approximately 4% of the human genome actively used by cells to
produce proteins. The information developed for human cDNAs
includes both the DNA sequence and the pattern of cDNA expression
in different tissues and developmental stages. He explained that much
more information is generated than can be protected effectively by
patents. Thus, while HGS files patent applications on commercially
valuable cDNAs, it also licenses proprietary databases of genome
9 Jeffrey N. Gibbs, The Human Genome, FDA and Product Liability, 7 Risk 267
(1996) (includes brief biographical information).
10 Susan J. Timian & D. Michael Connolly, The Regulation and Development of
Bioremediation, 7 Risk 279 (1996) (includes brief biographical information).
11 The use of biological organisms or substances to convert hazardous waste into
reusable or nontoxic products.
12 Dr. Benson is Vice President, General Counsel and Secretary, Human Genome
Sciences. He received his B.S. (Chemistry) and Ph.D. (Molecular Biology) from the
University of Florida.
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sequence information - with special efforts to make it available for
scientific research in nonprofit institutions.
Conclusion
Discoveries in biotechnology are made at an extraordinary rate. As
noted by several speakers whose papers appear here, such discoveries
have the potential to improve our environment, health, food supply
and, indeed, our world. As noted by others, these discoveries also are
subject to abuse and, even when helpful, can created ethical or social
problems.
The following papers offer many suggestions for promoting useful
biotechnological innovation and avoiding the downside of some
discoveries. The challenge is to encourage the technology and harvest its
many manifestly valuable fruits while avoiding possible physical and
societal damage. To that end, it is hoped that readers will find them
valuable.
